We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
nanoTherics Launches the magnefect-nano™ for Improved Gene Transfection
Product News

nanoTherics Launches the magnefect-nano™ for Improved Gene Transfection

nanoTherics Launches the magnefect-nano™ for Improved Gene Transfection
Product News

nanoTherics Launches the magnefect-nano™ for Improved Gene Transfection


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "nanoTherics Launches the magnefect-nano™ for Improved Gene Transfection"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

nanoTherics has announced launch of the magnefect-nano™, a new device for improved gene transfection. The system uses a unique technique applying proprietary magnet configurations and oscillating array systems to promote particle/DNA uptake into cells thus significantly improving non-viral gene transfection whilst maintaining cell viability.

The system is designed by the company to provide improved transfection efficiency and effectiveness (up to 1000 x) over the best currently available cationic lipid agents at short transfection times.

Dr Linda Cammish, Chief Executive Officer, said, “We are delighted to be offering this new product to enable our customers to improve their transfection efficiencies with even the most hard to transfect cells”. She added, “We are committed to product development to meet our customers needs and aim to introduce a range of additional products throughout 2009. The in-vivo potential of this technology is particularly exciting, which is an area we will be placing particular focus on.”
Advertisement